Brief Communications Arising | Published:

Safikhani et al. reply

Nature volume 540, pages E6E8 (01 December 2016) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Consistency in drug response profiling. Nature 540 (2016)

  2. 2.

    et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389–393 (2013)

  3. 3.

    et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012)

  4. 4.

    et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012)

  5. 5.

    et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov . 3, 1416–1429 (2013)

  6. 6.

    et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333–337 (2016)

  7. 7.

    et al. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget (2016)

  8. 8.

    et al. Drug response consistency in CCLE and CGP. Nature 540, (2016)

  9. 9.

    et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics 32, 1244–1246 (2016)

  10. 10.

    et al. Revisiting inconsistency in large pharmacogenomic studies. F1000Research (2016)

  11. 11.

    , , & Ten simple rules for reproducible computational research. PLoS Comput. Biol. 9, e1003285 (2013)

Download references

Author information

Affiliations

  1. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.

    • Zhaleh Safikhani
    • , Petr Smirnov
    • , Mark Freeman
    •  & Benjamin Haibe-Kains
  2. Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada.

    • Zhaleh Safikhani
    •  & Benjamin Haibe-Kains
  3. Institut de recherches cliniques de Montréal, Montreal, Quebec H2W 1R7, Canada.

    • Nehme El-Hachem
  4. Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.

    • Anna Goldenberg
  5. Department of Computer Science, University of Toronto, Toronto, Ontario M5S 2E4, Canada.

    • Anna Goldenberg
    •  & Benjamin Haibe-Kains
  6. The Francis Crick Institute, London NW1 1AT, UK.

    • Nicolai J. Birkbak
  7. University College London Cancer Institute, London WC1E 6BT, UK.

    • Nicolai J. Birkbak
  8. Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

    • Andrew H. Beck
  9. Harvard Medical School, Boston, Massachusetts 02115, USA.

    • Andrew H. Beck
    •  & Hugo J. W. L. Aerts
  10. Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

    • Hugo J. W. L. Aerts
    •  & John Quackenbush
  11. Brigham and Women’s Hospital, Boston, Massachusetts 02115, USA.

    • Hugo J. W. L. Aerts
  12. Harvard TH Chan School of Public Health, Boston, Massachusetts 02115, USA.

    • John Quackenbush
  13. Ontario Institute of Cancer Research, Toronto, Ontario M5G 1L7, Canada.

    • Benjamin Haibe-Kains

Authors

  1. Search for Zhaleh Safikhani in:

  2. Search for Nehme El-Hachem in:

  3. Search for Petr Smirnov in:

  4. Search for Mark Freeman in:

  5. Search for Anna Goldenberg in:

  6. Search for Nicolai J. Birkbak in:

  7. Search for Andrew H. Beck in:

  8. Search for Hugo J. W. L. Aerts in:

  9. Search for John Quackenbush in:

  10. Search for Benjamin Haibe-Kains in:

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Methods, Supplementary Text and Data, Supplementary Figure 1 and additional references.

  2. 2.

    Supplementary Data 1

    This file shows drug dose-response curves from the FIMM dataset. When the same drug was tested on the same cell line in CGP and/or CCLE, the curves were also displayed for comparison.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature20172

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing